JZJohannes Zander

Johannes Zander

*This is an algorithmically generated author record based on publicly available information.

Johannes Zander has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Population pharmacokinetics of piperacillin based on multicenter data to support model-informed precision dosing in critically ill women

    by Sebastian Greppmair, Sina Pesthy, Michael Zoller, Christina Scharf, Alexander Brinkmann, Otto Frey, Johannes Zander, Nadine Liebchen, Stefan Hagel, Sebastian G. Wicha, et al.

    Sex-specific differences in pharmacokinetics are increasingly recognized as clinically relevant, yet most population pharmacokinetic models for antibiotics have been developed in predominantly male populations with limited transferability to female patients. This study aimed to develop and externally evaluate a population pharmacokinetic model of piperacillin specifically for critically ill women to support model-informed precision dosing (MIPD). A total of 923 samples from 165 critically ill women (from four previously published studies) receiving piperacillin/tazobactam were analyzed. The data set was randomly split into a training set (80%) and an independent external evaluation set (20%). Non-linear mixed-effects modeling was employed based on the training data using NONMEM, and covariates were identified using stepwise covariate modeling with cross-validation. Prediction accuracy and bias were quantified using the median prediction error (MDPE) and the median absolute prediction error (MDAPE) in an MIPD scenario. Model predictions for future concentrations were generated both a priori and through Bayesian forecasting based on one prior sample. A two-compartment model provided the best fit for the data. Clearance was significantly affected by renal function estimated by the Cockcroft–Gault equation, along with procalcitonin and serum albumin. The external evaluation demonstrated strong predictive performance with very low systematic bias. In the MIPD scenario, a priori predictions exhibited good predictive performance (MDPE < |5.2|%, MDAPE < 33.4%), which substantially improved with Bayesian forecasting (MDPE < |3.2|%, MDAPE < 19.1%). A female-specific population pharmacokinetic model of piperacillin was developed and externally validated, demonstrating robust predictive performance and clear benefits for Bayesian forecasting.

  • Open Access

    Empirical linezolid target attainment in critically ill patients: integrating local susceptibility data and dosing strategies

    by Johannes Starp, Antonia Leonhardt, Jette Jung, Maximilian Sachsenberg Stoschus, Michael Zoller, Christina Scharf, Johannes Zander, Michael Paal, Sebastian G. Wicha, Uwe Liebchen

    Linezolid is important for treating infections caused by Gram-positive bacteria resistant to first-line agents. Severe infections often require empirical therapy before pathogen identification and susceptibility testing. This evaluation aims to compare different empirical linezolid dosing strategies in intensive care unit (ICU) patients to improve pharmacokinetic/pharmacodynamic target attainment while minimising toxicities. Three dosing strategies were compared: (i) standard dosing, (ii) therapeutic drug monitoring (TDM)-guided dosing, and (iii) a theoretical model-informed precision dosing (MIPD) strategy based on Bayesian forecasting with a population pharmacokinetic model. Each scenario was combined with an ICU-specific minimal inhibitory concentration (MIC) distribution comprising more than 19,000 isolates collected over 10 years. Data from 117 critically ill patients with 2184 TDM samples were available. Linezolid resistance was highest in ICU isolates (9.6%) compared with isolates from the intermediate care unit (4.3%), general wards (3.6%), and emergency room (1.6%). Among ICU isolates, resistance increased significantly over the 10-year study period, from 6.3% in 2015 to 11.4% in 2024. Empirical target attainment was 36.6% with standard dosing and 48.5% with TDM-guided dose adaptation, in two different ICU cohorts that showed 35.9% and 59.4% baseline target attainment, respectively. Theoretical MIPD projected target attainment in 71.4–81.6% of patients. After excluding resistant isolates, the corresponding values were 40.5%, 53.7%, and 79.0–90.3%, respectively. Integrating a large contemporary ICU-specific MIC distribution with patient-level pharmacokinetic data, our results suggest MIPD may represent a promising strategy improving target attainment, in contrast to standard regimens and TDM-guided dosing which failed to achieve adequate target exposure in ICU patients.

  • Open Access

    Rising resistance to linezolid among critically ill patients calls for model-informed precision dosing in empirical setting

    by Johannes Starp, Antonia Leonhardt, Jette Jung, Maximilian Stoschus, Michael Zoller, Christina Scharf, Johannes Zander, Michael Paal, Sebastian G. Wicha, Uwe Liebchen

    Objectives: Linezolid is highly valuable for treating infections caused by Gram-positive bacteria that are resistant to first-line agents. Severe infections require empirical therapy, where treatment is initiated before the pathogen and its susceptibility are identified. This evaluation aims to compare different dosing strategies for empirical dosing of linezolid in an intensive care unit (ICU) setting, with the goal of optimising pathogen eradication while minimising toxicities. Methods: Three dosing strategies were compared, all based on two previously published datasets of prospective clinical studies: (i) standard dosing, (ii) therapeutic drug monitoring (TDM) guided dosing, and (iii) a theoretical model-informed precision dosing (MIPD) guided by a population pharmacokinetic model using a Bayesian approach. Each scenario was combined with an ICU-specific minimal inhibitory concentration (MIC) distribution sampled over ten years and containing over 19,000 pathogens. The pharmacokinetic-pharmacodynamic target for pathogen eradication was defined as the minimum concentration above the MIC, and the toxicity limit was set at minimum concentrations exceeding 8 mg/L. Results: Data from 117 critically ill patients with 2184 TDM samples were available. Within the past 10 years, the rate of resistance to linezolid has increased significantly among intensive care patients, rising from 6.3% in 2015 to 11.4-15% between 2021 and 2024. Using standard dosing, only 35.7% of patients were within the target range. This number increased slightly to 46.3% when dose adaptations with TDM were possible. In contrast, MIPD projected target attainment in 70.9-81.3% of patients. Conclusions: In the era of increasing antimicrobial resistance, particularly against linezolid, novel dosing strategies such as MIPD become urgently necessary. Our results suggest that empirical linezolid dosing based on standard regimens as well as dose adaptation based on TDM failed to achieve sufficient target concentrations in ICU patients. Dosing guided by MIPD should therefore be further explored and implemented in future clinical practice.

  • Open Access

    Comparing posaconazole and itraconazole for antifungal prophylaxis in critically ill lung transplant recipients: Efficacy and plasma concentrations

    by Simon Kallee, Christina Scharf, Ines Schroeder, Michael Paal, Michael Vogeser, Michael Irlbeck, Johannes Zander, Michael Zoller, Jette Jung, Nikolaus Kneidinger, et al.

    Background: Posaconazole and itraconazole are commonly used for systemic antifungal prophylaxis after lung transplantation. The aim of this study on critically ill lung transplant recipients was to assess the rate of adequate plasma concentrations and the frequency of fungal‐induced transitions from antifungal prophylaxis to therapy after the administration of either posaconazole or itraconazole for systemic prophylaxis.Methods: Critically ill lung transplant recipients with postoperative posaconazole or itraconazole prophylaxis and therapeutic drug monitoring from February 2016 to November 2019 were retrospectively included in the study. Positive fungal cultures or Aspergillus antigen tests resulting in a transition from antifungal prophylaxis to therapy were analyzed from the first day of prophylaxis until 7 days after the last sample for each patient. Adequate plasma concentrations were defined as ≥500 µg/L for itraconazole and ≥700 µg/L for posaconazole.Results: Two hundred seventy‐five samples from 73 patients were included in the analysis. Overall, 60% of the posaconazole and 55% of the itraconazole concentrations were subtherapeutic. Administration of posaconazole suspension resulted significantly (P < .01) more often in subtherapeutic concentrations than tablets (68% vs 10%). Patients treated with posaconazole showed less positive fungal records resulting in a transition from prophylaxis to therapy than patients treated with itraconazole (10% vs 33%, P‐value: .029). The detection of a fungal pathogen was not associated with the measured plasma concentrations or the achievement of the target concentrations.Conclusion: Our findings suggest that posaconazole should be used instead of itraconazole for systemic prophylaxis in critically ill lung transplant recipients.


  • The influence of different procedures of general anaesthesia on platelet function, coagulation and the fibrinolytic system

    by H. M. Loick, Chr. Goenner‐Radig, H. Ostermann, J. L. Theissen, J. Zander

    We investigated whether different procedures during general anaesthesia alter platelet activation in vivo and/or activate coagulation and fibrinolysis. Forty-one healthy adult patients, scheduled for elective ophthalmic surgery under general anaesthesia, were studied with regard to changes of plasma beta-thromboglobulin (beta TG, index of platelet activation), thrombin-antithrombin III-complex (TAT, index of activation of coagulation) and d-dimer (index of fibrinolysis) during anaesthesia. The patients underwent either inhalation anaesthesia with enflurane and nitrous oxide or balanced anaesthesia with enflurane (0.5% end-tidal concentration) and alfentanil. Ten minutes after intubation the beta TG level was significantly reduced compared to the preoperative value in both general anaesthesia groups. Balanced anaesthesia caused a moderate but significant increase of TAT values at 10 min after extubation. No significant change in d-dimer levels was seen. Presuming a minimal effect of the surgical procedure on the determined variables, we conclude that none of the anaesthetic procedures induces platelet activation and fibrinolysis. The clinical relevance of the moderate coagulation activation during balanced anaesthesia remains to be investigated.